System readiness for DMTs in Alzheimer's disease

Dementia Academy will host a live webinar on Monday, 25th November at 16:00. You are invited to watch the webinar from your computer or tablet. We will be live for 1 hour via Zoom and a recording will be available following the meeting.

CPD accreditation

We will appy for CPD accreditation from the Royal College of Physicians for this webinar.

Objectives

• To appreciate an approach to ascertaining the number of potentially eligible patients for DMTs within a region
  
• To see the application of a framework to address system readiness to deliver DMTs for Alzheimer disease
• To understand motivations to accept DMTs in the general public, including 'willingness to pay'

Webinar outline

New drug treatments with the potential to modify Alzheimer disease (AD) are now becoming available, posing a challenge for integration into existing healthcare systems. Understanding public attitudes toward these treatments is essential. This study investigates public perspectives on the acceptability of disease-modifying therapies (DMTs) for AD, awareness of prevention/treatment, perceived benefits or risks, and willingness to pay (WTP) for DMTs. Here, we present an outline of how to ascertain numbers of potential eligible patients for DMTs, the components required to ensure a health system is 'ready' to deliver the treatments, and insights into public and patient acceptability of the treatments.

If you have any questions or queries please don't hesitate to contact us at events@neurologyacademy.org